Group items tagged

This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when associated with HIV/AIDS. Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. In studies with a large number of sites, it is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration.

Through this Funding Opportunity Announcement (FOA), the National Institute of Mental Health (NIMH) seeks applications to develop, sustain, enhance, and enrich a centralized national biorepository for genetic studies of psychiatric disorders for facilitation and acceleration of the scientific understanding of the genetic risk architecture underlying mental disorders. This effort is expected to involve a functionally integrated, multi-disciplinary team that will provide for open sharing of biosamples and data resources through a single, centralized, national resource to advance basic and translational research in the genetics of mental disorders.

The overall goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. The FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as surrogate markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays thus developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline by assessing the impact of therapeutic targets and treatment candidates on neurobiological mechanisms of clinical relevance to mental illnesses.

The Trinity Challenge is an initiative led by some of the world's most prominent organisations from across the private, academic, and social sectors for the purpose of sourcing and scaling solutions that better protect one billion more people from future health emergencies. It is a call to action for the world's best and brightest minds to contribute ideas and innovations, with £10M in awards for the best Challenge Teams. Questions cover economics, behavioural sciences, epidemiology, and many other disciplines. Founding Members and Members will contribute their data, resources, and time to catalyse and support the work of Challenge Teams.

The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.

The purpose of this Notice of Special Interest (NOSI) is to encourage research focused on Black child and adolescent suicide. Recent data suggest that Black youth, especially those under age 13, appear to be at higher than average risk for suicide and suicide-related behaviors.

Competitive applications will focus on studies that achieve one or more of the following goals: - Characterize disease progression for people with Parkinson's - Evaluate the utility of different instruments and/or instrument sub-items in measuring burden of disease, especially in individuals within the first two (2) years of Parkinson's diagnosis - Identify the role of pharmacological, medical device and/or non-medical interventions on managing Parkinson's symptoms and long-term health outcomes - Predict the future health status of participants without Parkinson's based on disease risk variables and model their likelihood of developing Parkinson's - Determine elements of disease experience that drive patient preference and risk tolerance - Explore the factors that affect volunteer compliance and completeness of participation in an online study - Determine how economic factors, patient-physician communication and lifestyle factors influence medical treatment and long-term health outcomes in people with Parkinson's - Analyst's choice: Researchers can submit their own analysis topics based on available Fox Insight data especially as it relates to longitudinal analyses

The OFRN Round 5 Opportunity Announcement is focused on expanding Ohio's research and development capabilities across the state's academic institutions and business in support of Ohio-based federal partner needs, which ultimately promotes Ohio's economic growth. OFRN Round 5 Areas of Interest (AOIs) include topics in Unmanned Aerial Systems (UAS), Artificial Intelligence, Human Factors, Data Analytics and Space Commercialization. This announcement seeks to leverage Ohio's unique research capabilities and its federal partner's expertise to accelerate technology development and innovation by increasing collaboration across government, academic, and industry organizations. The Round 5 Opportunity Announcement is subject to funding availability based upon a pending review and final determination of the Program Objectives from the Ohio Department of Higher Education (ODHE). This is a Pre-Release notification and NOT a formal solicitation.

For FY2021, Artificial Intelligence (AI) and Quantum Information Science and Engineering (QISE) have been added to the national priority areas in which the NRT Program encourages proposals. We seek proposals on any interdisciplinary research theme of national priority, with special emphasis on AI and QISE and the six research areas within NSF's 10 Big Ideas. The NSF research Big Ideas are Harnessing the Data Revolution (HDR), The Future of Work at the Human-Technology Frontier (FW-HTF), Navigating the New Arctic (NNA), Windows on the Universe: The Era of Multi-Messenger Astrophysics (WoU), The Quantum Leap: Leading the Next Quantum Revolution (QL), and Understanding the Rules of Life: Predicting Phenotype (URoL). Proposals that align with one of these designated priority areas should contain a title to reflect that alignment, as described in the program solicitation (e.g., NRT-AI: title, NRT-HDR: title, NRT-QL: title). Proposals may be submitted under two tracks (i.e., Track 1 and Track 2). Track 1 proposals may request a total budget (up to five years in duration) up to $3 million for projects with a focus on STEM graduate students in research-based PhD and/or master's degree programs. Track 2 proposals may request a total budget (up to five years in duration) up to $2 million; NSF requires that Track 2 proposals focus on programs from institutions not classified as Doctoral Universities: Very High Research Activity (R1). Requirements for Track 1 and Track 2 are identical.

Studies of novel treatments include, but are not limited to behavioral, pharmacological, physiological, learning- and device-based treatment approaches. This FOA provides support for up to two years (Phase I; R21) for protocol development, target identification and studies to confirm target engagement (i.e., link targets with tangible outcomes); followed by up to 3 years of support (Phase II; R33) for replication studies of addiction treatment across 2 or more settings. Specifically, this latter phase will focus on clinical trials that apply the target in a treatment setting (development, refinement, and/or adaptation) to evaluate the feasibility of conducting a larger trial.